Niels Erik Skakkebaek

Niels Erik Skakkebaek

Auto-generated profile, based on publicly available information

Niels Erik Skakkebaek

Department of Growth & Reproduction and EDMaRC, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
NSNiels E. Skakkebæk
Niels E. Skakkebæk
RLRune Lindahl-Jacobsen
Rune Lindahl-Jacobsen
HLHagai Levine
Hagai Levine
AAAnna-Maria Andersson
Anna-Maria Andersson
NJNiels Jørgensen
Niels Jørgensen
AJAnders Juul
Anders Juul

22 December 2014 in Environmental Health
Verified
Journal Article
Open access
PDF file
RZR Thomas Zoeller
R Thomas Zoeller
ÅBÅke Bergman
Åke Bergman
GBGeorg Becher
Georg Becher
PBPoul Bjerregaard
Poul Bjerregaard
Riana BornmanRiana Bornman
Riana Bornman
LVLaura N Vandenberg
Laura N Vandenberg
Several recent publications reflect debate on the issue of “endocrine disrupting chemicals” (EDCs), indicating that two seemingly mutually exclusive perspectives are being articulated separately and independently. Considering this, a group of scientists with expertise in basic science, medicine and risk assessment reviewed the various aspects of the debate to identify the most significant areas of dispute and to propose a path forward. We identified four areas of debate. The first is about the definitions for terms such as “endocrine disrupting chemical”, “adverse effects”, and “endocrine system”. The second is focused on elements of hormone action including “potency”, “endpoints”, “timing”, “dose” and “thresholds”. The third addresses the information needed to establish sufficient evidence of harm. Finally, the fourth focuses on the need to develop and the characteristics of transparent, systematic methods to review the EDC literature. Herein we identify areas of general consensus and propose resolutions for these four areas that would allow the field to move beyond the current and, in our opinion, ineffective debate.

1 October 1999 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
EMEwa Rajpert-De Meyts
Ewa Rajpert-De Meyts
NJNiels Jørgensen
Niels Jørgensen
NGNiels Græm
Niels Græm
JMJørn Müller
Jørn Müller
RCRichard L. Cate
Richard L. Cate
NSNiels E. Skakkebæk
Niels E. Skakkebæk
The ontogeny of expression of anti-Müllerian hormone (AMH) was examined by immunohistochemistry in 135 human gonadal tissue specimens of various developmental age, ranging from 6 weeks of fetal development to 38 yr of postnatal age. The series included specimens from normal testes and ovaries and from individuals either with pathological conditions affecting gonadal development or with idiopathic infertility manifested as azoospermia or severe oligozoospermia. AMH expression was found only in Sertoli and granulosa cells. A 6-week-old fetal testis at the indifferent gonad stage did not yet express AMH. The protein was first visible at 8.5 weeks of development, when sex cords have not yet been formed. Afterward, a majority of testicular specimens, including those from pathological conditions, strongly expressed AMH through fetal development and childhood until puberty. Markedly prolonged expression of AMH was observed in a 20-yr-old 46,XY female with androgen insensitivity syndrome, who retained prepubertal testicular morphology. In normal testes, the switch-off of AMH expression was usually associated with the appearance of primary spermatocytes, suggesting that their presence had an inhibitory effect on AMH. However, in adolescent boys lacking germ cells because of cancer treatment and in a majority of infertile adult men with idiopathic germ cell aplasia, AMH expression was also down-regulated despite the complete lack of spermatogenesis. The decrease in AMH expression thus reflects the terminal differentiation of Sertoli cells and is probably only partially dependent upon a regulatory factor associated with the onset of meiosis. In fetal ovaries, AMH was first detected at 36 weeks gestation in granulosa cells of preantral follicles. Thus, the onset of ovarian expression is at the end of fetal life and not in infancy as previously reported.

5 June 2014 in Environmental Health
Verified
Journal Article
Open access
PDF file
PRPanu Veikko Rantakokko
Panu Veikko Rantakokko
KMKatharina M. Main
Katharina M. Main
CWChristine Wohlfart-Veje
Christine Wohlfart-Veje
HKHannu Kiviranta
Hannu Kiviranta
RARiikka Airaksinen
Riikka Airaksinen
HVHelena E Virtanen
Helena E Virtanen
Humans are exposed to tributyltin (TBT), previously used as an antifouling paint in ships, mainly through fish consumption. As TBT is a known obesogen, we studied the association of placenta TBT and other organotin compounds (OTCs) with ponderal index (PI) and growth during the first 18 months of life in boys.

16 September 2022 in Human Reproduction
Verified
Journal Article
Open access
PDF file
LBLars Björndahl
Lars Björndahl
CBChristopher L R Barratt
Christopher L R Barratt
DMDavid Mortimer
David Mortimer
Ashok AgarwalAshok Agarwal
Ashok Agarwal
RARobert John Aitken
Robert John Aitken
AZArmand Zini
Armand Zini
Biomedical science is rapidly developing in terms of more transparency, openness and reproducibility of scientific publications. This is even more important for all studies that are based on results from basic semen examination. Recently two concordant documents have been published: the 6th edition of the WHO Laboratory Manual for the Examination and Processing of Human Semen, and the International Standard ISO 23162:2021. With these tools, we propose that authors should be instructed to follow these laboratory methods in order to publish studies in peer-reviewed journals, preferable by using a checklist as suggested in an Appendix to this article.

1 May 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MWM.J. Wensink
M.J. Wensink
YLYing Lu
Ying Lu
LTLu Tian
Lu Tian
GSGary Shaw
Gary Shaw
SRSilvia Rizzi
Silvia Rizzi
MEMichael L Eisenberg
Michael L Eisenberg
Diabetes reduces semen quality and increasingly occurs during reproductive years. Whether diabetes medications have glucose-independent effects on the male reproductive system is uncertain. This st... Visual Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring. Diabetes reduces semen quality and increasingly occurs during reproductive years. Whether diabetes medication... Background: Diabetes reduces semen quality and increasingly occurs during reproductive years. Diabetes medications, such as metformin, have glucose-independent effects on the male reproductive syst...